GRFS vs BHVN

Grifols, S.

A. (GRFS) offers the better valuation at 12. 1x trailing P/E (9. 4x forward), making it the more compelling value choice. Analysts rate Grifols, S. A. (GRFS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Biohaven Ltd.

(BHVN) delivered a total return of +35. 1%, compared to -53. 6% for Grifols, S. A. (GRFS). Over 10 years, the gap is even starker: BHVN returned +35. 1% versus GRFS's -35. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Grifols, S.

A. (GRFS) is the lower-risk stock at 1. 10β versus Biohaven Ltd. 's 1. 23β — meaning BHVN is approximately 12% more volatile than GRFS relative to the S&P 500. On balance sheet safety, Grifols, S. A. (GRFS) carries a lower debt/equity ratio of 115% versus 5% for Biohaven Ltd. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Grifols, S.

A. grew EPS 147. 8% year-over-year, compared to 26. 1% for Biohaven Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Grifols, S.

A. (GRFS) is the more profitable company, earning 5. 3% net margin versus 0. 0% for Biohaven Ltd. — meaning it keeps 5. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GRFS leads at 16. 4% versus 0. 0% for BHVN. At the gross margin level — before operating expenses — GRFS leads at 35. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, GRFS (2.

6% yield) pays a dividend. BHVN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Grifols, S.

A. (GRFS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10), 2. 6% yield). Both have compounded well over 10 years (GRFS: -35. 2%, BHVN: +35. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GRFS is a small-cap deep-value stock; BHVN is a small-cap quality compounder stock. GRFS pays a dividend while BHVN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.